← All trials
NCT05077085
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Jul 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Oct 13, 2021
- Last posted
- Oct 25, 2021
- Enrollment
- 66
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Leiden UniversityLead sponsor
- OLVG hospital, AmsterdamCollaborator
- University of AmsterdamCollaborator
- Erasmus University RotterdamCollaborator
- Leiden UniversityReponsible party - principal investigator
- Leiden UniversityOverall official - principal investigator
- Medical Center HaaglandenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.